2022年8月 | 失败临床研究TOP10
[1] https://www.innate-pharma.com/media/all-press-releases/innate-pharma-provides-update-astrazeneca-sponsored-interlink-1-phase-3-study
[2] https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-leap-002-trial-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-versus-lenvima-monotherapy-in-patients-with-unresectable-hepatocellul/;https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-921-trial-evaluating-keytruda-pembrolizumab-plus-chemotherapy-in-patients-with-metastatic-castration-resistant-prostate-cancer/
[3] https://www.sanofi.com/en/media-room/press-releases/2022/2022-08-17-05-30-00-2499668
[4] https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-canopy-study-evaluating-canakinumab-adjuvant-treatment-non-small-cell-lung-cancer
[5] https://www.pfizer.com/news/announcements/pfizer-discontinue-development-program-pf-07265803-lmna-related-dilated
[6] https://news.bms.com/news/details/2022/Late-Breaking-Results-From-Phase-2-AXIOMATIC-SSP-Study-of-Milvexian-an-Investigational-Oral-Factor-XIa-Inhibitor-Show-Favorable-Antithrombotic-Profile-in-Combination-With-Dual-Antiplatelet-Therapy/default.aspx
[7] https://investors.nuvationbio.com/news/news-details/2022/Nuvation-Bio-Announces-Discontinuation-of-NUV-422-Clinical-Development-Program/default.aspx
[8] https://www.pieris.com/investors/news-events/press-releases/detail/684/pieris-pharmaceuticals-reports-second-quarter-2022
[9] https://www.kaziatherapeutics.com/site/pdf/1b5d12dc-8773-4d4e-9b13-a94018071107/GBM-Agile-Update.pdf
[10] https://ir.aptinyx.com/press-releases/news-details/2022/Aptinyx-Reports-Results-from-Phase-2b-Study-of-NYX-2925-in-Fibromyalgia/default.aspx